https://spypharm.com/rss/latest-posts SpyPharm | Pharmaceutical News, Developments & Trends & Latest Posts en Copyright 2023 Spypharm & All Rights Reserved. https://spypharm.com/fda-approves-mesoblasts-ryoncil-for-sr-agvhd-treatment https://spypharm.com/fda-approves-mesoblasts-ryoncil-for-sr-agvhd-treatment Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/palleon-and-shanghai-henlius-biotech-link-on-autoimmune-therapy https://spypharm.com/palleon-and-shanghai-henlius-biotech-link-on-autoimmune-therapy Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/astellas-and-sangamo-sign-capsid-deal-for-neurological-diseases https://spypharm.com/astellas-and-sangamo-sign-capsid-deal-for-neurological-diseases Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/magazine-us-reproductive-laws-could-limit-womens-participation-in-clinical-trials https://spypharm.com/magazine-us-reproductive-laws-could-limit-womens-participation-in-clinical-trials Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/vertexs-stock-hurt-after-non-opioid-pain-drug-shows-benefit-similar-to-placebo https://spypharm.com/vertexs-stock-hurt-after-non-opioid-pain-drug-shows-benefit-similar-to-placebo Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/msd-makes-obesity-play-in-up-to-2bn-deal-for-hansohs-glp-1ra-asset https://spypharm.com/msd-makes-obesity-play-in-up-to-2bn-deal-for-hansohs-glp-1ra-asset Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/fda-approves-ionis-tryngolza-for-fcs-treatment https://spypharm.com/fda-approves-ionis-tryngolza-for-fcs-treatment Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/novo-nordisk-takes-a-hit-as-cagrisema-underperforms-in-weight-loss https://spypharm.com/novo-nordisk-takes-a-hit-as-cagrisema-underperforms-in-weight-loss Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/fda-confirms-end-of-eli-lillys-tirzepatide-shortage-after-re-evaluation https://spypharm.com/fda-confirms-end-of-eli-lillys-tirzepatide-shortage-after-re-evaluation Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/setback-for-uk-pharma-as-government-sets-unexpectedly-high-vpag-payback-rate-in-2025 https://spypharm.com/setback-for-uk-pharma-as-government-sets-unexpectedly-high-vpag-payback-rate-in-2025 Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/novo-nordisk-invests-12bn-in-new-denmark-facility https://spypharm.com/novo-nordisk-invests-12bn-in-new-denmark-facility Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/oncology-rd-emerging-therapies-and-new-challenges https://spypharm.com/oncology-rd-emerging-therapies-and-new-challenges Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/fda-targets-more-online-vendors-selling-unapproved-glp-1ra-products https://spypharm.com/fda-targets-more-online-vendors-selling-unapproved-glp-1ra-products Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/gilead-and-terray-link-to-develop-small-molecule-therapies https://spypharm.com/gilead-and-terray-link-to-develop-small-molecule-therapies Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/egyptian-drug-authority-approves-lilly-and-evas-insulin-injection https://spypharm.com/egyptian-drug-authority-approves-lilly-and-evas-insulin-injection Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/novo-holdings-completes-catalent-acquisition-for-165bn https://spypharm.com/novo-holdings-completes-catalent-acquisition-for-165bn Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/abera-and-orexo-partner-for-vaccine-powder-formulations https://spypharm.com/abera-and-orexo-partner-for-vaccine-powder-formulations Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/pharmas-data-and-analytics-market-forecast-to-reach-to-21bn-by-2028 https://spypharm.com/pharmas-data-and-analytics-market-forecast-to-reach-to-21bn-by-2028 Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/the-healthcare-sector-must-change-its-industrial-refrigeration-methods-to-reduce-its-emissions https://spypharm.com/the-healthcare-sector-must-change-its-industrial-refrigeration-methods-to-reduce-its-emissions Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/petrovax-announces-positive-results-from-long-cov-iii-21-trial-of-longidaza-for-long-term-pulmonary-sequelae-of-covid-19 https://spypharm.com/petrovax-announces-positive-results-from-long-cov-iii-21-trial-of-longidaza-for-long-term-pulmonary-sequelae-of-covid-19 Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/corcepts-als-modulator-fails-to-meet-primary-endpoint-in-phase-2-study https://spypharm.com/corcepts-als-modulator-fails-to-meet-primary-endpoint-in-phase-2-study Wed, 18 Dec 2024 06:00:13 -0500 spectro https://spypharm.com/fda-identifies-further-safety-concerns-with-intercepts-liver-drug https://spypharm.com/fda-identifies-further-safety-concerns-with-intercepts-liver-drug Wed, 18 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/ro-partners-with-eli-lilly-to-offer-zepbound-a-weight-loss-medication-in-single-dose-vials https://spypharm.com/ro-partners-with-eli-lilly-to-offer-zepbound-a-weight-loss-medication-in-single-dose-vials Wed, 18 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/denmarks-hta-evolution https://spypharm.com/denmarks-hta-evolution Tue, 17 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/small-cell-lung-cancer-navigating-the-global-clinical-trial-landscape https://spypharm.com/small-cell-lung-cancer-navigating-the-global-clinical-trial-landscape Tue, 17 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents https://spypharm.com/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents Tue, 17 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/cto-europe-2024-keep-the-burden-of-trials-away-from-patients-say-experts https://spypharm.com/cto-europe-2024-keep-the-burden-of-trials-away-from-patients-say-experts Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/gsks-lung-cancer-therapy-gains-ema-prime-designation https://spypharm.com/gsks-lung-cancer-therapy-gains-ema-prime-designation Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/bavarian-nordic-signs-mpox-vax-deal-with-serum-institute-of-india https://spypharm.com/bavarian-nordic-signs-mpox-vax-deal-with-serum-institute-of-india Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/adcs-breach-barriers-to-become-mainstream-cancer-treatment https://spypharm.com/adcs-breach-barriers-to-become-mainstream-cancer-treatment Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/fda-approves-galdermas-nemluvio-to-treat-atopic-dermatitis https://spypharm.com/fda-approves-galdermas-nemluvio-to-treat-atopic-dermatitis Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/the-future-of-third-party-logistics-in-an-evolving-biopharmaceutical-world https://spypharm.com/the-future-of-third-party-logistics-in-an-evolving-biopharmaceutical-world Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/reprieve-for-wuxi-as-biosecure-vote-likely-pushed-to-2025 https://spypharm.com/reprieve-for-wuxi-as-biosecure-vote-likely-pushed-to-2025 Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-cullinan-therapeuticss-cln-619 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-cullinan-therapeuticss-cln-619 Sun, 15 Dec 2024 06:00:13 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-avidity-biosciencess-aoc-1020 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-avidity-biosciencess-aoc-1020 Sun, 15 Dec 2024 06:00:13 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-in8bios-inb-400 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-in8bios-inb-400 Sun, 15 Dec 2024 06:00:12 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-vigil-neurosciences-iluzanebart https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-vigil-neurosciences-iluzanebart Sun, 15 Dec 2024 06:00:12 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-aquestive-therapeuticss-epinephrine https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-aquestive-therapeuticss-epinephrine Sun, 15 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-jazz-pharmaceuticalss-jzp-898 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-jazz-pharmaceuticalss-jzp-898 Sun, 15 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-solid-biosciencess-sgt-003 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-solid-biosciencess-sgt-003 Sun, 15 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-forte-biosciencess-fb-102 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-forte-biosciencess-fb-102 Sun, 15 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-tenaya-therapeuticss-tn-401 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-tenaya-therapeuticss-tn-401 Sun, 15 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-crispr-therapeuticss-ctx-131 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-crispr-therapeuticss-ctx-131 Sun, 15 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/carisma-to-undergo-staff-and-clinical-candidate-restructuring-to-stretch-cash-reserves https://spypharm.com/carisma-to-undergo-staff-and-clinical-candidate-restructuring-to-stretch-cash-reserves Sat, 14 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/bioage-halts-phase-2-obesity-study-just-two-months-after-ipo https://spypharm.com/bioage-halts-phase-2-obesity-study-just-two-months-after-ipo Sat, 14 Dec 2024 06:00:06 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-i-mabs-lemzoparlimab https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-i-mabs-lemzoparlimab Fri, 13 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-clesacostat-tromethamine-ervogastat https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-clesacostat-tromethamine-ervogastat Fri, 13 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-adicet-bios-adi-001 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-adicet-bios-adi-001 Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-eli-lilly-and-cos-imlunestrant-tosylate https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-eli-lilly-and-cos-imlunestrant-tosylate Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-novartiss-rapcabtagene-autoleucel https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-novartiss-rapcabtagene-autoleucel Fri, 13 Dec 2024 06:00:10 -0500 spectro